Dapagliflozin: Cost-Effectiveness as an Add-On Therapy to Metformin in the Treatment of Type 2 Diabetes (T2DM) in Argentina and Chile
Value in Health - United Kingdom
doi 10.1016/j.jval.2014.03.1449
Full Text
Open PDFAbstract
Available in full text
Date
May 1, 2014
Authors
Publisher
Elsevier BV